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2Incidence of atrial ﬁbrillation in patients with
mild to severe obstructive sleep
apnea and pacemakersTable 1
General features of patients at baseline.
Mild OSA Severe OSA P value
N 108 93 –
Age, years 62.3 ± 13.2 59.5 ± 14.6 0.1550
Body mass index, kg/m2 29.4 ± 5.6 28.1 ± 6.0 0.1140
Male sex (%) 80 (74%) 65 (70%) 0.5314
White ethnicity (%) 78 (72%) 63 (68%) 0.5378
Type 2 diabetes mellitus
(%)
60 (56%) 40 (43%) 0.0900
Creatinine, mg/dL 0.82 ± 0.45 0.90 ± 0.62 0.2921
eGFR, mL/min/1.73 m2
(CKD-EPI)
95.3 ± 17.0 91.4 ± 22.3 0.1617
Albumin:creatinine ratio,
mg/g
19.4 ± 7.6 17.8 ± 10.3 0.2078
Hypertension (%) 90 (83%) 84 (90%) 0.2128
Mean 24-hour ABPM,
mmHg
134.9 ± 9.1/88.6
± 12.2
136.7 ± 8.0/91.7
± 11.8
0.1410/0.9235
Dual chamber pacemaker 108 (100%) 93 (100%) 1.0000
Apnea/hypopnea index,
events/h
13.5 ± 8.3 46.4 ± 15.8 b0.0001
Antihypertensive agents
ACE inhibitors/ARB 75 (69%) 56 (60%) 0.1841
Diuretics 90 (83%) 68 (73%) 0.0876
DHP Ca++ channel
blockers
86 (73%) 57 (61%) 0.0775
Values are presented as Mean ± SD or %; ABPM, ambulatory blood pressure measure-
ments; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD-
EPI, Chronic Kidney Disease Epidemiology Collaboration; DHP, dihydropyridine; eGFR, es-
timated glomerular ﬁltration rate; HR, heart rate; N, number of patients; OSA, obstructive
sleep apnea.Keywords:
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Obstructive sleep apnea (OSA) may lead to atrial ﬁbrillation (AF), a
common cardiac arrhythmia. In a previous report, AF occurred in 4.8%
of patients in the breathing sleep disorder group (N = 228), but only
in 0.9% of those without such disorders (P = 0.003) [1]. Further, AF
can be a contributing factor for various diseases such as cerebral or sys-
temic embolism [2]. Thus, AF conversion is crucial to reduce cardiovas-
cular morbidity and mortality [3,4]. Particularly, OSA is a risk factor for
stroke and hypertension [5,6]. Further, continuous positive airway pres-
sure (CPAP) reduces death and cardiovascular events and improves hy-
pertension control [7,8]. Furthermore, OSA has been shown to be
independently associated with AF development [9], with a prevalence
rate as high as 50% [10]. Several underlyingmechanisms are attributable
for OSA-induced AF. The main mechanism is intermittent nighttime
desaturation [1,11]. Nighttime hypoxemia secondary to OSA may
cause atrial remodeling and dilatation, conduction abnormalities,
vagal tone hyperfunction, pulmonary vasoconstriction/hypertension,
or increase in inﬂammatorymarkers [11–16]. Accentuated sympathetic
nerve activity is a robust risk factor for cardiovascular events, such as ce-
rebral infarction andmyocardial infarction [17]. Peripheral sympathetic
nerve activity is accentuated in patients with hypertension, congestive
heart failure, OSA, obesity, diabetes, and chronic renal illnesses. At
least 50% of hypertensive subjects show potentiated sympathetic
nerve activity [18,19].
We aim to compare the incidence of AF events in patients with mild
vs. severe OSA, recorded by the pacemakers 6 months previously to
polysomnography. This retrospective study involved 201 hypertensive
patients divided intomildOSA (n=108) and severeOSA (n=93), nor-
mal renal function, and pacemaker implanted due to sinus node disease
(Table 1). The study was conducted in accordance with the Helsinki
declaration and was approved by the ethics committee of our institu-
tion. All patients signed the informed consent before inclusion. Patients
were evaluated between January 2013 and January 2016 at the Arrhyth-
mias and Artiﬁcial Cardiac Pacing Service at Hospital e Clínica São
Gonçalo, Rio de Janeiro, Brazil. Patients who met the following criteria
were consecutively enrolled: (i) dual chamber pacemaker due to sinus
node disease; (ii) Mild OSA: 5 to 15 Apnea/Hypopnea index (AHI)
events/h; (iii) Severe OSA: N30 AHI events/h; (iv) age between 18 and
80 years; (v) structurally normal heart to myocardial scintigraphy,
without ischemia, ﬁbrosis area, previously diagnosed; (vi) glomerular
ﬁltration rate estimated by the Chronic Kidney Disease Epidemiologyhttp://dx.doi.org/10.1016/j.ijcme.2016.09.001
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlCollaboration (CKD-EPI equation [20], eGFR N60 mL/min/1.73 m with-
out microalbuminuria); and (vii) capacity to read, comprehend, and
sign the informed consent form and attend the clinical tests. Patients
that presented any of the subsequent criteria were excluded:
(i) pregnancy; (ii) valvular disease with signiﬁcant adverse sequelae;
(iii) unstable angina, myocardial infarction, transient ischemic attack
or stroke; (iv) renovascular abnormalities; (v) psychiatric disease; (vi)
known addiction to drugs or alcohol that affects the intellect; (vii) seri-
ous health condition that, in the investigator's opinion, may adversely
affect the safety and/or efﬁcacy of the participant or the study; (viii)
congestive heart failure of functional class II to IV according to the
New York Heart Association. The primary endpoint was to record epi-
sodes at least of 30-s duration of AF registered by the pacemaker.
The 24-hour ABPM [21], polysomnography [22] and pacemaker
follow-up were previously described [23]. The results are expressed as
mean and standard deviation for normally distributed data and asmedi-
an with interquartile range otherwise. All statistical tests were two-
sided. Comparisons between two-paired values were performed with
the paired t-test in cases of normally distributed variables, and by the
Wilcoxon test in cases of non-normally distributed variables. Compari-
sons between more than two-paired values were made by repeated-
measures analysis of variance or by Kruskal–Wallis analysis of variancee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Percentage of atrial ﬁbrillation (AF) occurrence recorded by the pacemakers during
the 6 months before the realization of the polysomnography; OSA, obstructive sleep
apnea; Mild OSA, n = 108; Severe OSA, n = 93.
16 Letter to the Editoras appropriate, complemented by a post-hoc test. Categorical variables
were comparedwith Fisher's exact test. A P-value b0.05was considered
signiﬁcant. Correlations between two variables were performed by
Pearson's chi-square test in case of a Gaussian distribution and with
the Spearman correlation test otherwise. All statistical analyses were
performed using the program Graphpad Prism v 7.0 (Graphpad Soft-
ware, La Jolla, CA, USA).
Analyzing the AF events recorded by the pacemakers during the
6months before the realization of the polysomnography, AF occurrence
was much higher in the group with severe OSA (67 individuals or
62.04%) than in the group presenting mild OSA (21 subjects or
23.58%), odd ratio [OR] 5.603, 95% conﬁdence interval [CI]
3.021–10.110, P b 0.0001) by Fisher's exact test (Fig. 1). Our data
showed that, in patients with severe OSA, the risk of AF occurrence is
muchhigher than in patients onlywithmild OSA, being all events exact-
ly recorded by the pacemakers.
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